{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:51Z","timestamp":1793943711851,"version":"4.8.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study evaluating D-R vs R maintenance in patients with newly diagnosed multiple myeloma (NDMM) who had very good or better partial response, were minimal residual disease (MRD)-positive (10\u20135) and anti-CD38\u2013na\u00efve after transplant. Two hundred patients were randomly assigned (1:1) to D-R (n = 99) or R (n = 101) maintenance for up to 36 cycles. The MRD-negative (10\u20135) conversion rate by 12\u00a0months from start of maintenance (primary end point) was significantly higher for D-R\u00a0than R (50.5% vs 18.8%; odds ratio [OR], 4.51; 95% confidence interval [CI], 2.37-8.57; P\u00a0&amp;lt; .0001). MRD-negative (10\u20136) conversion rate was similarly higher with D-R (23.2% vs 5.0%; OR, 5.97; 95% CI, 2.15-16.58; P\u00a0=\u00a0.0002). At median follow-up (32.3 months), D-R achieved a higher overall MRD-negative (10\u20135) conversion rate (D-R, 60.6% vs R, 27.7%; OR, 4.12; 95% CI, 2.26-7.52; P\u00a0&amp;lt; .0001) and complete response rate or better (75.8% vs 61.4%; OR, 2.00; 95% CI, 1.08-3.69; P\u00a0=\u00a0.0255) vs R. Progression-free survival (PFS) favored D-R vs R (hazard ratio, 0.53; 95% CI, 0.29-0.97); estimated 30-month PFS rates were 82.7% for D-R and 66.4% for R. Incidences of grade 3\/4 cytopenias (54.2% vs 46.9%) and infections (18.8% vs 13.3%) were slightly higher with D-R than R. In conclusion, D-R maintenance achieved a higher MRD-negative conversion rate and improved PFS after transplant vs R, with no new safety concerns. This trial was registered at www.clinicaltrials.gov as #NCT03901963.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025746","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:58:46Z","timestamp":1727459926000},"page":"300-310","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-0188","authenticated-orcid":false,"given":"Ashraf","family":"Badros","sequence":"first","affiliation":[{"name":"1Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laahn","family":"Foster","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Myeloma, Waldenstrom\u2019s and Amyloidosis Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-2217","authenticated-orcid":false,"given":"Chakra P.","family":"Chaulagain","sequence":"additional","affiliation":[{"name":"4Myeloma and Amyloidosis Program, Department of Hematology and Oncology, Cleveland Clinic Florida, Weston, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Pettijohn","sequence":"additional","affiliation":[{"name":"5The Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"6Division of Medical Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[{"name":"7Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine-Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"10Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Silbermann","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[{"name":"12Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-5456","authenticated-orcid":false,"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[{"name":"12Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krevvata","sequence":"additional","affiliation":[{"name":"13Janssen Research and Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[{"name":"14Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Patel","sequence":"additional","affiliation":[{"name":"15Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-1079","authenticated-orcid":false,"given":"Vipin","family":"Khare","sequence":"additional","affiliation":[{"name":"15Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelore","family":"Cortoos","sequence":"additional","affiliation":[{"name":"15Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"13Janssen Research and Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Lin","sequence":"additional","affiliation":[{"name":"15Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[{"name":"16Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2025011616203242700_bib1","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"2025011616203242700_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025011616203242700_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"23","key":"2025011616203242700_bib4","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"2025011616203242700_bib5","unstructured":"International Myeloma Foundation\n          . A\u00a0historic turning point: ODAC unanimously votes in favor of MRD testing as an early endpoint in myeloma clinical trials to support accelerated approvals of new treatments. Accessed 14 June 2024. https:\/\/www.myeloma.org\/blog\/dr-duries\/odac-unanimously-in-favor-mrd-testing-early-endpoint-myeloma."},{"key":"2025011616203242700_bib6","volume-title":"Darzalex (daratumumab). Package insert.","year":"2023"},{"key":"2025011616203242700_bib7","volume-title":"Darzalex Faspro (daratumumab and hyaluronidase-fihj). Package insert.","year":"2024"},{"issue":"8","key":"2025011616203242700_bib8","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025011616203242700_bib9","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025011616203242700_bib10","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025011616203242700_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv"},{"issue":"10192","key":"2025011616203242700_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"suppl 15","key":"2025011616203242700_bib13","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2021.39.15_suppl.8004","article-title":"Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA part 2","volume":"39","author":"Moreau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025011616203242700_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025011616203242700_bib15","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025011616203242700_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"2025011616203242700_bib17","author":"Sonneveld","year":"13  16  2024"},{"issue":"5","key":"2025011616203242700_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"2025011616203242700_bib19","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/300\/2351623\/blood_bld-2024-025746-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/3\/300\/2351623\/blood_bld-2024-025746-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T16:20:44Z","timestamp":1737044444000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/3\/300\/518000\/Daratumumab-with-lenalidomide-as-maintenance-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025746","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]}}}